Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nicholls

Showing results (1281-1290 of 1,396) with videos related to

Pageof 140
Sort By:
Heart, Lung & Circulation|January 27, 2023
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation RecommendationsNatalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Circulation Reports|December 11, 2025
Sex Differences in Polyvascular Disease　- Implications for Lipid-Lowering Management and Cardiovascular OutcomesAya Katasako-Yabumoto, Yu Kataoka, Eri Kiyoshige, et al.
European Heart Journal. Cardiovascular Imaging|February 25, 2026
Achieved LDL-C Levels <55 mg/dL and Cardiac Events in Patients and Lesions Harbouring Lipid-rich Plaque PhenotypesYu Kataoka, Stephen J Nicholls, Eri Kiyoshige, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2018
VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemiaCarla M Cannizzo, Aaron A Adonopulos, Emma L Solly, et al.
American Journal of Human Genetics|July 16, 2013
ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathyTobias B Haack, Robert Kopajtich, Peter Freisinger, et al.
Journal of Clinical Lipidology|April 12, 2025
Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experienceMitchell Sarkies, David Sullivan, Andrew Black, et al.
Scientific Reports|September 13, 2018
The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesisSamuel T Hourigan, Emma L Solly, Victoria A Nankivell, et al.
Lancet (London, England)|September 4, 2025
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trialSubodh Verma, Lawrence A Leiter, Hwee Teoh, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
JAMA|November 16, 2016
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
Pageof 140

Showing results (1281-1290 of 1,396) with videos related to

Sort By:
Pageof 140
Heart, Lung & Circulation|January 27, 2023
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation RecommendationsNatalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Circulation Reports|December 11, 2025
Sex Differences in Polyvascular Disease　- Implications for Lipid-Lowering Management and Cardiovascular OutcomesAya Katasako-Yabumoto, Yu Kataoka, Eri Kiyoshige, et al.
European Heart Journal. Cardiovascular Imaging|February 25, 2026
Achieved LDL-C Levels <55 mg/dL and Cardiac Events in Patients and Lesions Harbouring Lipid-rich Plaque PhenotypesYu Kataoka, Stephen J Nicholls, Eri Kiyoshige, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2018
VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemiaCarla M Cannizzo, Aaron A Adonopulos, Emma L Solly, et al.
American Journal of Human Genetics|July 16, 2013
ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathyTobias B Haack, Robert Kopajtich, Peter Freisinger, et al.
Journal of Clinical Lipidology|April 12, 2025
Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experienceMitchell Sarkies, David Sullivan, Andrew Black, et al.
Scientific Reports|September 13, 2018
The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesisSamuel T Hourigan, Emma L Solly, Victoria A Nankivell, et al.
Lancet (London, England)|September 4, 2025
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trialSubodh Verma, Lawrence A Leiter, Hwee Teoh, et al.
JAMA|January 30, 2019
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart DiseaseBrian A Ference, John J P Kastelein, Kausik K Ray, et al.
JAMA|November 16, 2016
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
Pageof 140